Adaptive Biotechnologies Corporation

MUN:1HM Stock Report

Market Cap: €664.7m

Adaptive Biotechnologies Valuation

Is 1HM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1HM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 1HM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 1HM's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1HM?

Key metric: As 1HM is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1HM. This is calculated by dividing 1HM's market cap by their current revenue.
What is 1HM's PS Ratio?
PS Ratio3.9x
SalesUS$177.28m
Market CapUS$692.15m

Price to Sales Ratio vs Peers

How does 1HM's PS Ratio compare to its peers?

The above table shows the PS ratio for 1HM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3x
EVT Evotec
1.9x12.1%€1.5b
GXI Gerresheimer
1.3x10.2%€2.6b
1SXP SCHOTT Pharma KGaA
4.2x10.7%€4.0b
SRT3 Sartorius
4.4x9.3%€13.4b
1HM Adaptive Biotechnologies
3.9x18.5%€692.1m

Price-To-Sales vs Peers: 1HM is expensive based on its Price-To-Sales Ratio (3.9x) compared to the peer average (3x).

Price to Sales Ratio vs Industry

How does 1HM's PS Ratio compare vs other companies in the European Life Sciences Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
1HM 3.9xIndustry Avg. 4.3xNo. of Companies9PS03.26.49.612.816+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 1HM is good value based on its Price-To-Sales Ratio (3.9x) compared to the European Life Sciences industry average (4.3x).

Price to Sales Ratio vs Fair Ratio

What is 1HM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1HM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.9x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 1HM's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1HM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€7.00
0%
18.4%€9.44€5.19n/a6
Nov ’25n/a
€6.51
0%
21.7%€9.19€5.05n/a6
Oct ’25n/a
€6.24
0%
23.0%€9.13€4.56n/a6
Sep ’25n/a
€6.24
0%
23.0%€9.13€4.56n/a6
Aug ’25n/a
€5.89
0%
28.3%€9.31€4.65n/a6
Jul ’25n/a
€5.89
0%
28.3%€9.31€4.65n/a6
Jun ’25n/a
€5.89
0%
28.3%€9.31€4.65n/a6
May ’25n/a
€6.15
0%
28.3%€9.23€4.61n/a6
Apr ’25n/a
€6.34
0%
25.9%€9.28€4.64n/a6
Mar ’25n/a
€6.34
0%
25.9%€9.28€4.64n/a6
Feb ’25n/a
€7.92
0%
23.7%€10.05€5.48n/a6
Jan ’25n/a
€8.45
0%
21.3%€10.14€5.53n/a6
Dec ’24n/a
€8.45
0%
21.3%€10.14€5.53n/a6
Nov ’24€4.16
€11.06
+166.0%
15.6%€14.16€8.50n/a7
Oct ’24n/a
€11.77
0%
11.1%€14.04€10.29n/a7
Sep ’24n/a
€10.79
0%
19.0%€13.63€6.36n/a8
Aug ’24n/a
€11.45
0%
20.6%€13.61€6.35n/a8
Jul ’24n/a
€11.45
0%
20.6%€13.61€6.35n/a8
Jun ’24n/a
€11.45
0%
20.6%€13.61€6.35n/a8
May ’24n/a
€11.91
0%
20.6%€14.15€6.60n/a8
Apr ’24n/a
€11.91
0%
20.6%€14.15€6.60n/a8
Mar ’24n/a
€11.91
0%
20.6%€14.15€6.60n/a8
Feb ’24n/a
€12.26
0%
25.5%€16.97€6.60n/a8
Jan ’24n/a
€12.25
0%
25.3%€16.96€6.59n/a7
Dec ’23n/a
€12.04
0%
31.2%€17.96€6.98n/a7
Nov ’23n/a
€13.26
0%
34.9%€21.07€7.52€4.167

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$707.40

7D

-0.9%

1Y

-3.6%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

7D

1.3%

1Y

89.7%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

3.6%

1Y

22.9%